GlassScriptPhysician profile
Nadeem A Akbar
NPI 1740307644
$32,230.71
in general payments reported to CMS, 2019-2025
15 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 83% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,304 · 2020: $2,897 · 2021: $3,343 · 2022: $2,609 · 2023: $1,588 · 2024: $17K · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $4,336 · Travel and Lodging: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,195.00 |
| Food and Beverage | $4,336.33 |
| Travel and Lodging | $1,547.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $10,937.76 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Acclarent, INC | $5,384.72 | 2019-2024 | Trudi Nav Cable |
| Aerin Medical INC. | $3,412.60 | 2020-2025 | |
| Optinose US, INC. | $3,074.97 | 2019-2025 | |
| Intersect Ent, INC. | $2,441.88 | 2019-2021 | |
| Neurent Medical Limited | $2,091.04 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Stryker Corporation | $1,463.37 | 2019-2024 | Scopis Ent, Xpress Loprofile, Shaver System |
| Medtronic, INC. | $1,360.39 | 2022-2025 | Stealthstation S8 Platform, Midas Rex, Straightshot |
| Medtronic USA, INC. | $1,123.57 | 2019-2020 | |
| 3-D Matrix, INC. | $342.03 | 2025 | |
| Genzyme Corporation | $185.38 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $179.69 | 2019 | |
| Glaxosmithkline, LLC. | $175.00 | 2021-2023 | Nucala |
| Checkpoint Surgical, INC | $30.56 | 2025 | Checkpoint Stimulators |
| Paratek Pharmaceuticals, INC. | $27.75 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.